View in EDS HTML Full Text PDF Full Text

OnabotulinumtoxinA in Resistant Depression: A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP Study).

Saved in:
Bibliographic Details
Title: OnabotulinumtoxinA in Resistant Depression: A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP Study).
Authors: Ceolato-Martin, Caroline (AUTHOR), Chevallier-Collins, Claire (AUTHOR), Clément, Jean-Pierre (AUTHOR), Charles, Eric (AUTHOR), Lacroix, Aurélie (AUTHOR), Ranoux, Danièle (AUTHOR), Ai, Sizhi (AUTHOR)
Source: Depression & Anxiety (1091-4269). 9/12/2024, Vol. 2024, p1-12. 12p.
Subjects: Hamilton Depression Inventory, Botulinum toxin, Botulinum A toxins, Sensorimotor cortex, Mental depression, Agitation (Psychology)
Abstract: Background: OnabotulinumtoxinA (OnaA) injection in glabella area appears to be a promising treatment for major depression. However, one major concern of placebo‐controlled studies on botulinum toxin injections is to ensure adequate blinding. Patients and Methods: In this context, all subjects of this trial received the active product (OnaA). After randomization, 58 patients with resistant major depressive disorder (MDD) received OnaA either in the glabella area (N = 29) or in the crow's feet area (N = 29). Subjects were blinded to the supposedly effective area against resistant depression and the examiner was not aware of the injected area. The primary outcome measure was the proportion of responders (50% or greater decrease in MADRS [Montgomery and Asberg Depression Rating Scale] score from baseline) in glabella group versus crow's feet group at week 6 after the OnaA injection. Results: The number of responders was significantly higher in the glabella group than in the crow's feet group with 13 responders out of 29 patients (44.8%) in the glabella group and five out of 28 patients (17.9%) in the crow's feet group (p = 0.029). The rate of psychomotor agitation as measured by item 9 of the Hamilton Depression Rating Scale (HAM‐D), associated with a shorter span of psychiatric disorder, was a potent positive predictive factor of positive response to treatment. Conclusion: We conclude that OnaA injected in the glabella muscles is an effective and well‐tolerated treatment for MDD. We suggest that patients with a high score at item 9 of the HAM‐D might be a subgroup of best responders. We assume that OnaA may act as a modulator of the activity of the primary sensorimotor cortex and then of the amygdala. Trial Registration: ClinicalTrials.gov identifier: NCT03484754 [ABSTRACT FROM AUTHOR]
Copyright of Depression & Anxiety (1091-4269) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 179608820
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: OnabotulinumtoxinA in Resistant Depression: A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP Study).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Ceolato-Martin%2C+Caroline%22">Ceolato-Martin, Caroline</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chevallier-Collins%2C+Claire%22">Chevallier-Collins, Claire</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Clément%2C+Jean-Pierre%22">Clément, Jean-Pierre</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Charles%2C+Eric%22">Charles, Eric</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lacroix%2C+Aurélie%22">Lacroix, Aurélie</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ranoux%2C+Danièle%22">Ranoux, Danièle</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ai%2C+Sizhi%22">Ai, Sizhi</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Depression+%26+Anxiety+%281091-4269%29%22">Depression & Anxiety (1091-4269)</searchLink>. 9/12/2024, Vol. 2024, p1-12. 12p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Hamilton+Depression+Inventory%22">Hamilton Depression Inventory</searchLink><br /><searchLink fieldCode="DE" term="%22Botulinum+toxin%22">Botulinum toxin</searchLink><br /><searchLink fieldCode="DE" term="%22Botulinum+A+toxins%22">Botulinum A toxins</searchLink><br /><searchLink fieldCode="DE" term="%22Sensorimotor+cortex%22">Sensorimotor cortex</searchLink><br /><searchLink fieldCode="DE" term="%22Mental+depression%22">Mental depression</searchLink><br /><searchLink fieldCode="DE" term="%22Agitation+%28Psychology%29%22">Agitation (Psychology)</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: OnabotulinumtoxinA (OnaA) injection in glabella area appears to be a promising treatment for major depression. However, one major concern of placebo‐controlled studies on botulinum toxin injections is to ensure adequate blinding. Patients and Methods: In this context, all subjects of this trial received the active product (OnaA). After randomization, 58 patients with resistant major depressive disorder (MDD) received OnaA either in the glabella area (N = 29) or in the crow's feet area (N = 29). Subjects were blinded to the supposedly effective area against resistant depression and the examiner was not aware of the injected area. The primary outcome measure was the proportion of responders (50% or greater decrease in MADRS [Montgomery and Asberg Depression Rating Scale] score from baseline) in glabella group versus crow's feet group at week 6 after the OnaA injection. Results: The number of responders was significantly higher in the glabella group than in the crow's feet group with 13 responders out of 29 patients (44.8%) in the glabella group and five out of 28 patients (17.9%) in the crow's feet group (p = 0.029). The rate of psychomotor agitation as measured by item 9 of the Hamilton Depression Rating Scale (HAM‐D), associated with a shorter span of psychiatric disorder, was a potent positive predictive factor of positive response to treatment. Conclusion: We conclude that OnaA injected in the glabella muscles is an effective and well‐tolerated treatment for MDD. We suggest that patients with a high score at item 9 of the HAM‐D might be a subgroup of best responders. We assume that OnaA may act as a modulator of the activity of the primary sensorimotor cortex and then of the amygdala. Trial Registration: ClinicalTrials.gov identifier: NCT03484754 [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Depression & Anxiety (1091-4269) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=179608820
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1155/2024/1177925
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 1
    Subjects:
      – SubjectFull: Hamilton Depression Inventory
        Type: general
      – SubjectFull: Botulinum toxin
        Type: general
      – SubjectFull: Botulinum A toxins
        Type: general
      – SubjectFull: Sensorimotor cortex
        Type: general
      – SubjectFull: Mental depression
        Type: general
      – SubjectFull: Agitation (Psychology)
        Type: general
    Titles:
      – TitleFull: OnabotulinumtoxinA in Resistant Depression: A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP Study).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ceolato-Martin, Caroline
      – PersonEntity:
          Name:
            NameFull: Chevallier-Collins, Claire
      – PersonEntity:
          Name:
            NameFull: Clément, Jean-Pierre
      – PersonEntity:
          Name:
            NameFull: Charles, Eric
      – PersonEntity:
          Name:
            NameFull: Lacroix, Aurélie
      – PersonEntity:
          Name:
            NameFull: Ranoux, Danièle
      – PersonEntity:
          Name:
            NameFull: Ai, Sizhi
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 09
              Text: 9/12/2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 10914269
          Numbering:
            – Type: volume
              Value: 2024
          Titles:
            – TitleFull: Depression & Anxiety (1091-4269)
              Type: main
ResultId 1